Arca
Skip to content
Tools
Tools

ANO1: Anoctamin-1

Calcium-activated chloride channel (CaCC).

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on ANO1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved1

  • Crofelemer

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        CrofelemerApprovedNAPO PharmaceuticalsSmall moleculeBlockerAnoctamin-1 blocker3

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 3 in all, from ClinicalTrials.gov.
        Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)CrofelemerPhase 2RecruitingNapo Therapeutics, S.p.A.Apr 1, 2025
        Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)CrofelemerPhase 2 / Phase 3Active, not recruitingNapo Pharmaceuticals, Inc.Dec 6, 2024
        Open-Label Pilot Study With Crofelemer in Patients With Short Bowel SyndromeCrofelemerEarly phase 1Active, not recruitingJessica SosioMar 22, 2024

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        Moyamoya disease 7
        0.58
        Diarrheal disease
        0.54
        Abnormality of the skeletal system
        0.54
        Diverticular disease
        0.43
        Cholelithiasis
        0.42
        Thrombophilia
        0.38
        Hypertensive disorder
        0.35
        Intestinal dysmotility syndrome
        0.34
        Female genital tract polyp
        0.34

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2046267, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q5XXA6, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.